A Phase 2 interventional study of Ruxolitinib and Anagrelide in MPN (Myeloproliferative Neoplasms), sponsored by Incyte Corporation. Terminated at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-19.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Thrombocythemia, Essential with a site in United States — 18 open to participants now, 32 under way, 6 of them phase 3. Thrombocythemia, Essential · United States.
Among the 149 studies in Thrombocythemia, Essential with a site in United States, this one is the 103rd largest by enrollment of the 120 interventional ones that give a count, is the only one that started in 2017, is one of 49 in phase 2, and was the 115th registered.
229 studies on the registry are indexed under Thrombocythemia, Essential; 38 are open to participants now.
Browse Thrombocythemia, Essential studies →18 of the 149 studies in Thrombocythemia, Essential with a site in United States are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Australia, Austria and 19 more countries
Ages 18+
Damora Therapeutics · Sites in United States, Australia
Ages 18+
Incyte Corporation · Sites in United States, Australia, Belgium and 8 more countries
Ages 18+
Incyte Corporation · Sites in United States, Australia, Belgium and 2 more countries
Ages 18+
MPN Research Foundation · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Thrombocythemia, Essential studies recruiting now, 30 (88%) set no upper age limit and 3 (9%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 66 · Phase 3 18
First in 1992; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 52 across 168 interventional studies indexed under Thrombocythemia, Essential.
Median enrollment 45 across the 120 interventional studies, 592 across the 13 observational. Of the 113 that completed or were terminated, 36 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 149 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
Incyte Corporation has 8 studies filed under Thrombocythemia, Essential — fewer than ten, so there is no comparison to draw.
10 of the studies in Thrombocythemia, Essential with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06079879Phase 3Merck Sharp & Dohme LLCA Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) | 2027-07-14 |
| NCT06456346Phase 3Merck Sharp & Dohme LLCBomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) | 2027-09-28 |
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT06063486University of Southern CaliforniaCurcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms | 2026-12-31 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 149 studies in Thrombocythemia, Essential with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.
229 studies on the registry are indexed under Thrombocythemia, Essential; 38 are open to participants now.
This study's enrollment of 12 is below the median of 52 across 168 interventional studies indexed under Thrombocythemia, Essential.
Browse Thrombocythemia, Essential studies →Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
Compared within Thrombocythemia, Essential, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myeloproliferative Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Resistant to or intolerant of hydroxyurea, that is, fulfilling at least 1 of the following criteria:
Exclusion Criteria:
Subjects previously treated with anagrelide or Hydroxyurea (HU).
Inadequate liver function at screening and Day 1 (before drug administration) as demonstrated by:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ruxolitinib or placebo will be administered orally twice a day at a starting dose of 10 mg.
Drug: Ruxolitinib · Drug: Placebo
Anagrelide or placebo will be administered orally twice a day at a starting dose of 1 mg. Use of anagrelide will be consistent with approved prescribing information.
Drug: Anagrelide · Drug: Placebo
Ruxolitinib administered orally twice daily (BID) at the protocol-defined starting dose.
Also known as: Jakafi, INCB018424
Anagrelide administered orally at a starting dose of 1 mg BID.
Anagrelide-placebo administered orally BID
Ruxolitinib-placebo administered orally BID.
Proportion of Subjects Who Achieve Platelet and White Blood Cell (WBC) Control
Defined as proportion of subjects who achieve a simultaneous reduction of platelet counts to \< 600 × 10\^9/L with a reduction of WBC counts to \< 10 × 10\^9/L for at least 80% of biweekly measurements for a consecutive 12-week period between Weeks 32 and 52.
Time frame: 52 weeks
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.
Time frame: Baseline through the end of randomized period -up to 14 months per participant
Proportion of Subjects Who Achieve Complete Remission or Partial Remission
Defined as proportion of subjects who achieve CR or PR at Week 32 based on European LeukemiaNet (ELN) 2013 response criteria. Per ELN criteria: Complete Remission: durable resolution of disease related signs and symptoms, durable blood count normalization, absence of hemorrhagic or thrombotic events, absence of signs of progressive disease and bone marrow histological remission including disappearance of megakaryocyte hyperplasia and absence of reticulin fibrosis \>Grade 1. Partial remission: durable resolution of disease related signs and symptoms, durable blood count normalization, absence of hemorrhagic or thrombotic events, absence of signs of progressive disease, persistance of megakaryocyte hyperplasia. No response: any response that does not satisfy partial remission. Progressive Disease: transformation in PET-MF, MDS or acute leukemia.
Time frame: 32 weeks
Time to Treatment Discontinuation
Defined as the time when treatment is discontinued
Time frame: 98 weeks
Duration of Response
Defined as measurement of response from the onset of response to the loss of response for responders.
Time frame: 142 weeks
Proportion of Subjects Who Achieve Reduction of Platelet Counts to < 600 × 10^9/L
Defined as Proportion of subjects who achieve reduction of platelet counts to \< 600 × 10\^9/L for at least 80% of biweekly measurements for a consecutive 12-week period between Weeks 32 and 52.
Time frame: Between 32 and 52 weeks
Proportion of Subjects Who Achieve a Reduction of WBC Counts to < 10 × 109/L
Defined as Proportion of subjects who achieve a reduction of WBC counts to \< 10 × 109/L for at least 80% of biweekly measurements for a consecutive 12-week period between Weeks 32 and 52.
Time frame: 52 weeks
Approximately 120 participants were planned for enrollment and 12 participants were enrolled (6 in the ruxolitinib group and 6 in the anagrelide group). The first participant was dosed on 14 Nov 2017 and Last participant completed study on 03 Aug 2020
| Milestone | Group A : Ruxolitinib and Anagrelide Placebo | Group B : Anagrelide and Ruxolitinib Placebo |
|---|---|---|
| Started | 6 | 6 |
| Completed | 0 | 0 |
| Not completed | 6 | 6 |
| Withdrew: Study terminated by sponsor | 2 | 5 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Physician decision | 2 | 1 |
Defined as proportion of subjects who achieve a simultaneous reduction of platelet counts to \< 600 × 10\^9/L with a reduction of WBC counts to \< 10 × 10\^9/L for at least 80% of biweekly measurements for a consecutive 12-week period between Weeks 32 and 52.
| proportion of participants | Group A : Ruxolitinib and Anagrelide Placebo | Group B : Anagrelide and Ruxolitinib PLacebo |
|---|---|---|
| Proportion of Subjects Who Achieve Platelet and White Blood Cell (WBC) Control | 0 | 0.17 |
Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.
| participants | Group A : Ruxolitinib and Anagrelide Placebo | Group B : Anagrelide and Ruxolitinib PLacebo |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 5 | 4 |
Defined as proportion of subjects who achieve CR or PR at Week 32 based on European LeukemiaNet (ELN) 2013 response criteria. Per ELN criteria: Complete Remission: durable resolution of disease related signs and symptoms, durable blood count normalization, absence of hemorrhagic or thrombotic events, absence of signs of progressive disease and bone marrow histological remission including disappearance of megakaryocyte hyperplasia and absence of reticulin fibrosis \>Grade 1. Partial remission: durable resolution of disease related signs and symptoms, durable blood count normalization, absence of hemorrhagic or thrombotic events, absence of signs of progressive disease, persistance of megakaryocyte hyperplasia. No response: any response that does not satisfy partial remission. Progressive Disease: transformation in PET-MF, MDS or acute leukemia.
| proportion of participants | Group A : Ruxolitinib and Anagrelide Placebo | Group B : Anagrelide and Ruxolitinib Placebo |
|---|---|---|
| Proportion of Subjects Who Achieve Complete Remission or Partial Remission | 0 | 0.17 |
Defined as the time when treatment is discontinued
| Days | Group A : Ruxolitinib and Anagrelide Placebo | Group B : Anagrelide and Ruxolitinib Placebo |
|---|---|---|
| Time to Treatment Discontinuation | 261.2 ± 238.85 | 437.2 ± 183.99 |
Defined as measurement of response from the onset of response to the loss of response for responders.
| Days | Group A : Ruxolitinib and Anagrelide Placebo | Group B : Anagrelide and Ruxolitinib PLacebo |
|---|---|---|
| Duration of Response | — | 442 |
Defined as Proportion of subjects who achieve reduction of platelet counts to \< 600 × 10\^9/L for at least 80% of biweekly measurements for a consecutive 12-week period between Weeks 32 and 52.
| Proportion of participants | Group A : Ruxolitinib and Anagrelide Placebo | Group B : Anagrelide and Ruxolitinib Placebo |
|---|---|---|
| Proportion of Subjects Who Achieve Reduction of Platelet Counts to < 600 × 10^9/L | 0 | 0.50 |
Defined as Proportion of subjects who achieve a reduction of WBC counts to \< 10 × 109/L for at least 80% of biweekly measurements for a consecutive 12-week period between Weeks 32 and 52.
| Proportion of participants | Group A : Ruxolitinib and Anagrelide Placebo | Group B : Anagrelide and Ruxolitinib PLacebo |
|---|---|---|
| Proportion of Subjects Who Achieve a Reduction of WBC Counts to < 10 × 109/L | 0 | 0.33 |
Collected over Baseline through the end of randomized period -up to 14 months per participant. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A : Ruxolitinib and Anagrelide Placebo | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Group B : Anagrelide and Ruxolitinib Placebo | 0/6 (0%) | 1/6 (16.7%) | 4/6 (66.7%) |
| Event | Group A : Ruxolitinib and Anagrelide Placebo | Group B : Anagrelide and Ruxolitinib Placebo |
|---|---|---|
| Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/5 | 1/6 |
| Event | Group A : Ruxolitinib and Anagrelide Placebo | Group B : Anagrelide and Ruxolitinib Placebo |
|---|---|---|
| FatigueGeneral disorders | 3/5 | 0/6 |
| AnaemiaBlood and lymphatic system disorders | 2/5 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 0/5 | 2/6 |
| NauseaGastrointestinal disorders | 1/5 | 2/6 |
| Oedema peripheralGeneral disorders | 0/5 | 2/6 |
| PruritusSkin and subcutaneous tissue disorders | 1/5 | 2/6 |
| Abdominal pain upperGastrointestinal disorders | 1/5 | 0/6 |
| Aspartate aminotransferase increasedInvestigations | 1/5 | 0/6 |
| Back painMusculoskeletal and connective tissue disorders | 1/5 | 0/6 |
| BronchitisInfections and infestations | 1/5 | 1/6 |
| Age, Continuous(years) | Group A : Ruxolitinib and Anagrelide Placebo | Group B : Anagrelide and Ruxolitinib Placebo | Total |
|---|---|---|---|
| Mean | 71.8 ± 13.04 | 61.2 ± 16.77 | 66.5 ± 15.37 |
| Sex: Female, Male(Participants) | Group A : Ruxolitinib and Anagrelide Placebo | Group B : Anagrelide and Ruxolitinib Placebo | Total |
|---|---|---|---|
| Female | 5 | 3 | 8 |
| Male | 1 | 3 | 4 |
| Race/Ethnicity, Customized(Participants) | Group A : Ruxolitinib and Anagrelide Placebo | Group B : Anagrelide and Ruxolitinib Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 5 | 11 |
| Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Group A : Ruxolitinib and Anagrelide Placebo | Group B : Anagrelide and Ruxolitinib Placebo | Total |
|---|---|---|---|
| White/Caucasian | 5 | 6 | 11 |
| Asian | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2017 to primary completion in Aug 2020, 32 months.
Results were first posted in Nov 2021, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib